IDH 2 is a novel diagnostic and prognostic serum biomarker for non‐small‐cell lung cancer

Author:

Li Jiang‐jiang1234,Li Ruilei5,Wang Wenxiang6,Zhang Baihua6,Song Xin5,Zhang Chunfang7,Gao Yang7,Liao Qianjin8,He Ya123,You Shuo9,Tan Zheqiong123,Luo Xiangjian123,Li Yueshuo123,Tang Min123,Weng Xinxian123,Yi Wei123,Peng Shifang10,Liu Shaohui11,Tan Ying11,Bode Ann M.12,Cao Ya123413

Affiliation:

1. Key Laboratory of Carcinogenesis and Invasion Chinese Ministry of Education Xiangya Hospital Central South University Changsha China

2. Cancer Research Institute Xiangya School of Medicine Central South University Changsha China

3. Key Laboratory of Carcinogenesis Chinese Ministry of Health Changsha China

4. Research Center for Technologies of Nucleic Acid‐Based Diagnostics and Therapeutics Hunan Province Changsha China

5. Cancer Biotherapy Center The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province) Kunming China

6. The 2nd Department of Thoracic Surgery Hunan Cancer Hospital The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China

7. Department of Thoracic Surgery Xiangya Hospital Central South University Changsha China

8. Key Laboratory of Translational Radiation Oncology Hunan Province Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China

9. Second Affiliated Hospital of Xiangya Central South University Changsha China

10. Department of Infectious Disease Xiangya Hospital Central South University Changsha China

11. Health Management Center Xiangya Hospital Central South University Changsha China

12. The Hormel Institute University of Minnesota Austin MN USA

13. National Joint Engineering Research Center for Genetic Diagnostics of Infectious Diseases and Cancer Changsha China

Funder

Natural Science Foundation of Hunan Province

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Reference41 articles.

1. Benefits and Harms of CT Screening for Lung Cancer

2. The first reported results of AG‐120, a first‐in‐class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1‐mutant solid tumors, including gliomas;Burris H;Mol Cancer Ther,2015

3. Cancer research: past, present and future

4. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer

5. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3